http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2469283-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f10ec45749ea9b78168a98bd19394909 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S436-811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-775 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5767 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-576 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7e6e177fde0c2960a6c82eaec848331 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8da5aa05a53cddf610ea51defc2552a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1274983eaea7b844acd8f9cc9f697b19 |
| publicationDate | 2012-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2469283-A1 |
| titleOfInvention | Clinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker. |
| abstract | The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analysed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-alpha-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and beta2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers. |
| priorityDate | 2006-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 301.